Tachyon Therapeutics
San Francisco
About Tachyon Therapeutics
Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer. The company is currently conducting Phase 1 clinical research in patients with advanced cancer to assess the safety, pharmacokinetics, and anti-tumor effectiveness of TACH101. The programs will be advanced in a timely, innovative, high-quality, and scientifically sound manner.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $18.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2023)
- Website: tachyontx.com
- Phone: (628) 216-5899
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/tachyon-therapeutics-107582 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.